IP Library Granted Patent US 7,144,729
Granted Patent B2
US 7,144,729 · App. 10/324,257 · Granted Dec 5, 2006

Methods and compositions for tissue regeneration

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,144,729
App. No.
10/324,257
Granted
Dec 5, 2006
Kind
B2
Abstract

The present invention provides the use and composition of matter of angiogenic or other growth/cytokine factors expressed by mixtures of allogeneic human cell strains or lines of various types and stages of differentiation. Also provided are unencapsulated preparations (mixed with or applied to extracellular matrix material or synthetic biocompatible substances) for the purpose of temporary application to wounds or defects in the skin or other tissues for the restoration of blood supplying connective tissue to enable organ-specific cells to reestablish organ integrity as well as to inhibit excessive scar formation.

Claims (22)

1. A tissue regeneration system comprising:

(a) a first component comprising fibrinogen, wherein the first component is in the form of a spray; and

(b) a second component comprising thrombin and mitotically inactivated allogeneic cells, wherein the second component is in the form of a spray and wherein the cells comprise one or more keratinocytes and fibroblasts that secrete one or more biologically active molecules selected from the group consisting of GM-CSF, VEGF, KGF, bFGF, TGFβ, angiopoietin, EGF, IL-Iβ, IL-6, IL-8, TGFα, and TNFα.

2. The tissue regeneration system of claim 1 , wherein the one or more keratinocytes and fibroblasts are differentiated fibroblasts and keratinocytes.

3. The tissue regeneration system of claim 1 , wherein the one or more keratinocytes and fibroblasts are mitotically inactivated by administration of mitomycin C or other chemically-based mitotic inhibitors, irradiation with γ-Rays, irradiation with X-Rays, or irradiation with UV light.

4. The tissue regeneration system of claim 1 , wherein the first component further comprises a collagen, alginate, alginate beads, agarose, fibrin, fibrin glue, blood plasma, fibrin beads, laminin, proteoglycan, fibronectin, chitosan, or heparin.

5. The tissue regeneration system of claim 1 , wherein the second component further comprises a cryoprotectant.

6. The tissue regeneration system of claim 5 , wherein the cryoprotectant is selected from the group consisting of 10% by volume of a glycerol solution, 15% by volume of a glycerol solution, and 15% glycerol and 5% human serum albumin by volume of a solution.

7. The tissue regeneration system of claim 5 , wherein the cryoprotectant is glycerol.

8. A kit comprising, in one or more containers, the tissue regeneration system of claim 1 .

9. The kit of claim 8 , wherein the first component and the second component are cryopreserved prior to shipping and subsequently thawed prior to use.

10. The kit of claim 9 , wherein the first and second components are each contained in a separate vial having a removable screw cap, wherein the vial is sterile and is made of a material resistant to low temperatures and wherein the removable lid can be replaced with a spray pump following thawing of the first and second components prior to use.

11. The kit of claim 10 , wherein the spray pump delivers a volume of approximately 130 μl per spray.

12. The kit of claim 10 , wherein the material resistant to low temperatures is selected from the group consisting of glass, polypropylene, polyethylene, and ethylene vinyl acetate (EVA).

13. The kit of claim 10 , wherein the vials are sealed within a pouch or container prior to cryopreservation, wherein the pouch or container is fabricated of a material capable of withstanding temperatures ranging from −80° to −196° C. and wherein the pouch or container protects the first and second components from contamination during cryopreservation and subsequent thawing.

14. The kit of claim 13 , wherein the pouch or container is waterproof.

15. The tissue regeneration system of claim 1 , wherein the second component comprises from about 1 ×10 3 cells/μl to about 50 ×10 3 cells/μl of the mitotically inactive allogenic cells.

16. The tissue regeneration system of claim 3 , wherein the one or more keratinocytes and fibroblasts are mitotically inactivated by mitomycin C.

17. The tissue regeneration system of claim 3 , wherein the one or more keratinocytes and fibroblasts are mitotically inactivated by irradiation with γ-Rays.

18. The tissue regeneration system of claim 3 , wherein the one or more keratinocytes and fibroblasts are mitotically inactivated by irradiation with X-Rays.

19. The tissue regeneration system of claim 3 , wherein the one or more keratinocytes and fibroblasts are mitotically inactivated by irradiation with UV light.

20. The tissue regeneration system of claim 5 , wherein the cryoprotectant is human serum albumin.

Assignments (8)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 14, 2013
From: HEALTHPOINT INTERNATIONAL, LLC
To: SMITH & NEPHEW, INC.
Reel/Frame 029994/0633 →
CHANGE OF NAME Recorded Dec 17, 2012
From: DFB TECHNOLOGY HOLDINGS, LLC; HEALTHPOINT HOLDINGS, LLC
To: HEALTHPOINT INTERNATIONAL, LLC
Reel/Frame 029481/0540 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 14, 2010
From: DFB PHARMACEUTICALS, INC.
To: DFB TECHNOLOGY HOLDINGS, LLC
Reel/Frame 023788/0443 →
CORRECTIVE ASSIGNMENT TO CORRECT THE NAME OF THE ASSIGNOR FROM 'EPITECH SA' TO --EPISOURCE SA--. PREVIOUSLY RECORDED ON REEL 016862 FRAME 0490. ASSIGNOR(S) HEREBY CONFIRMS THE ENTIRE RIGHT, TITLE AND INTEREST FOR THE UNITED STATES AND IN ALL COUNTRIES.. Recorded Sep 21, 2007
From: EPISOURCE SA
To: DFB PHARMACEUTICALS, INC.
Reel/Frame 019864/0180 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 16, 2005
From: EPITECH SA
To: DFB PHARMACEUTICALS, INC.
Reel/Frame 016862/0490 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 10, 2004
From: ISOTIS SA
To: EPISOURCE SA
Reel/Frame 014969/0088 →
TO CORRECT SPELLING OF ASSIGNOR'S NAME, BEATRICE MIS, ON REEL/FRAME 013924/0649. Recorded Sep 10, 2003
From: ROLLAND, ERIC; HUNZIKER, THOMAS; MIS, BEATRICE; RINSCH, CHRISTOPHER
To: ISOTIS S.A.
Reel/Frame 014463/0684 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 4, 2003
From: ROLLAND, ERIC; HUNZIKER, THOMAS; MIS, BEATRIC; RINSCH, CHRISTOPHER
To: ISOTIS S.A.
Reel/Frame 013924/0649 →